中国脑癌药物ACT001(ACT001)获核准接受第三阶段试验,显示有希望延长脑转移的肺癌患者的存活期。 A Chinese brain cancer drug, ACT001, approved for phase III trials, shows promise in extending survival for lung cancer patients with brain metastases.

南开大学和Acccentatech在天津研制的脑癌药物ACT001获得核准,在中国开始第三阶段临床试验。 A brain cancer drug, ACT001, developed in Tianjin by Nankai University and Accendatech, has received approval to begin phase III clinical trials in China. 该药物旨在跨越血脑屏障,在早期试验中已显示出可喜的成果,使脑部转移的患者在与放射疗法或免疫疗法相结合的情况下从小细胞和非细胞肺癌中存活下来。 The drug, designed to cross the blood-brain barrier, has shown promising results in earlier trials, extending survival for patients with brain metastases from small and non-small cell lung cancer when combined with radiotherapy or immunotherapy. 它在中国、美国和欧洲赢得了突破和无主药物命名。 It has earned breakthrough and orphan drug designations in China, the U.S., and Europe. 即将进行的涉及约50家医院的第三阶段试验将评价其在较大群体中的效力和安全,预期在18个月左右取得结果。 The upcoming phase III trial, involving around 50 hospitals, will evaluate its effectiveness and safety in a larger group, with results expected in about 18 months.